IFI16 and systemic sclerosis: For example, patients with systemic lupus erythematosus, Sjögren Syndrome, and systemic sclerosis exhibit significantly elevated levels of anti-IFI16 antibodies [40,41,42], which can result from aberrant overexpression and mislocalization of IFI16 [43].